PharmaCyte Biotech Inc (OTCMKTS:PMCBD – Get Rating)'s stock price traded up 0.4% during trading on Tuesday . The stock traded as high as $2.88 and last traded at $2.84. 33,197 shares changed hands during mid-day trading, an increase of 276% from the average session volume of 8,831 shares. The stock had previously closed at $2.83.
PharmaCyte Biotech Price Performance
The company's 50 day simple moving average is $2.94 and its 200 day simple moving average is $2.86.
PharmaCyte Biotech Company Profile
(Get Rating)
PharmaCyte Biotech, Inc is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes.
Featured Articles
- Get a free copy of the StockNews.com research report on PharmaCyte Biotech (PMCBD)
- After an Earnings Blowout, Is Ciena Stock a Buying Opportunity?
- Meta Breaks Out Of A Base, Looks Like A Growth Stock Again
- Here's Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
- The Bottom Is In For McCormick & Company
- Walgreens Boots Alliance: Blue Chip, High-Yield Turnaround Story
Receive News & Ratings for PharmaCyte Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PharmaCyte Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
PharmaCyte Biotech Inc(OTCMKTS:PMCBD-GET Rating)周二股价上涨0.4%,最高报2.88美元,尾盘报2.84美元。午盘,33,197股易手,较8,831股的平均成交量增加276%。该股此前收盘报2.83美元。
PharmaCyte生物技术价格表现
该公司的50日简单移动均线切入位在2.94美元,200日简单移动均线切入位在2.86美元。
PharmaCyte生物技术公司简介
(获取评级)
PharmaCyte Biotech,Inc.是一家临床阶段生物技术公司,从事癌症和糖尿病治疗药物的开发和商业化。它专注于一种基于纤维素的专利活细胞封装技术,名为Cell-in-a-Box,该技术将被用作开发无法手术的胰腺癌和其他实体癌症肿瘤以及糖尿病治疗方法的平台。
专题文章
- 免费获取StockNews.com关于PharmaCyte Biotech(PMCBD)的研究报告
- 在盈利井喷之后,Ciena股票是买入机会吗?
- Meta突破A基点,看起来又成了成长股
- 这就是为什么维京治疗公司在肥胖药物数据上上涨了50%以上
- 麦考密克公司的底线已经到了
- 沃尔格林靴子联盟:蓝筹股,高收益扭亏为盈
接受PharmaCyte Biotech Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对PharmaCyte Biotech和相关公司的最新新闻和分析师评级的每日简要摘要。